Last week, magAssist’s second preclinical training on China’s first full-maglev extracorporeal VAD with the collaboration of Professor Nianguo DONG’s team of the Cardiovascular Surgery Department, Wuhan Union Hospital and Professor Jinsong HUANG’s team of the Cardiovascular Surgery Department, Guangdong Provincial People’s Hospital.
This training was divided into exploration on clinical application timing of extracorporeal artificial heart and surgical methods to be applied. The clinical team completed pipeline connection and machine operation on two sheep which soon came to life and stood up after the surgery.
Professor Jinsong HUANG said, “The device features easy use. We can feel that the device designer has made thoughtful consideration of human-factors engineering. We really hope that the clinical trials of extracorporeal VADs can be unfolded in our center and good technologies can be applied to the patients soon.”
Professor Ping LI noted, “Extracorporeal VADs are new clinical applications in China and an innovation of treatment concepts. It’s hoped that they can fill in the current clinical gap. In terms of support timing and method of blood flow circuit establishment, the overall treatment should be carefully selected on the premise of putting patients first.”
Professor Xufeng WEI pointed out, “Early this year, animal experiments based on GLP standard were completed to verify the safety of the VADs. This clinical training enabled experts from each center to experience the operation of the device and simulate the corresponding surgical methods on animals, which is of great significance to the formal clinical trials.”
Professors Jinsong HUANG, Mingjie MAI and Min WU, Surgical Experts of Guangdong Provincial People’s Hospital, Exchanged with Professor Xufeng WEI, Chief Scientist of Big Animal Center, on Surgical Methods and Device Operation
Professors Jinsong HUANG and Min WU Performed Intubation for Extracorporeal VAD System
A Photo of the Clinical and Engineering Team and the Awakened Animal Three Hours after the Operation
An extracorporeal VAD, commonly known as an extracorporeal artificial heart, can temporarily perform the functions of heart and gain the golden time for the transition to other treatment means or recovery of heart function after the heart loses its ability to pump blood as a result of myocardial infarction, acute attack of chronic heart failure, severe trauma, drowning and so on. At present, there is no domestically made extracorporeal artificial heart put into clinical practice in China. This pre-clinical application training will undoubtedly shed the light of hope for the millions of patients with cardiac arrest in China every year.
About the Clinical Team:
Over the past four decades, the Cardiovascular Surgery Department of Wuhan Union Hospital has grown into a cardiovascular surgery diagnosis and treatment center integrating domestically leading medical care, teaching and scientific research. In the past three years, the Department has secured its top five ranking in National Specialized Hospital Departments of Fudan University and maintained its first place in Central China. Among the fruitful academic achievements are several domestically leading and internationally advanced technologies, especially in cardiac surgery, heart transplant, pediatric heart transplant, valve research and development and other key areas of cardiac surgery. Clinically, Wuhan Union Hospital performed over 4,000 cardiac surgery procedures in 2019, including the greatest number of heart transplant procedures nationally. The Department is a National Key Clinical Specialization, one of the first Master’s and Doctoral Degree Awarding Units of the State Council, an undertaking unit of State Program 863 and Program 973 and National Key Research Plan, National Training Base for Cardiovascular Surgeons, Chinese Heart Transplant Training Base, National Regional Medical Center for Cardiovascular Diseases, Construction Unit for National Cardiovascular Disease Diagnosis and Treatment Ability Improvement Project, and Central China Cardiovascular Disease Diagnosis and Treatment Center. Over the past ten years, the Department has won such honorary titles as National Advanced Collective of Hygiene System, Nationwide Youth Civilization Collective, National Quality Service Position, National Demonstration Site of Learning-from-Lei Feng Activities and National Workers’ Pioneer Collective.
Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences) is located at 106 Zhongshan Second Road, Yuexiu District, Guangzhou, Guangdong Province. Built in 1946, Guangdong Provincial People’s Hospital has a gross floor area about 230,000 m2. It’s a Grade III Class A general hospital integrating medical treatment, scientific research, teaching, prevention, health care and rehabilitation, and a designated hospital of Guangzhou medical insurance. It’s also the Hospital Affiliated to South China University of Technology, South China Hospital Affiliated to Medical College, Shantou University, and Teaching Hospital of Guangdong Provincial Medical College. It has been awarded the honorary titles such as the Most Trusted Medical Institution in Mainland China by Hong Kong citizens, the National Earthquake Relief Hero Collective, the National Model Workers’ Home.
Founded in 2017, magAssist is headed by Dr. Po-Lin HSU, a special-term professor of Soochow University and an expert of National One Thousand Young Talents Project, composed of domestic and international teams long engaged in artificial heart research and development. On the basis of mechatronics, maglev and computational fluid dynamics and other core platform technologies, magAssist is committed to building a new-generation ECLS platform for severe acute patients. On the basis of full-maglev artificial heart, magAssist has developed ECLS systems for different groups of people, different auxiliary needs and different clinical scenarios like ECMO and minimally invasive interventional artificial heart, and serving cardiovascular patients in China and in the world at large. Within a span of 3 years, magAssist has completed the R&D of maglev extracorporeal artificial heart, the construction of China’s first maglev extracorporeal artificial heart production line and the GLP big animal experiments. Good results have been achieved in the experiments, and the products will be put into clinical trials at the end of 2020.